TrialCurveFAKTION: reconstructed Kaplan–Meier curves
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Lancet Oncol. 2020 Mar;21(3):345–57. doi: 10.1016/S1470-2045(19)30817-4 |
|---|---|
| DOI | 10.1016/S1470-2045(19)30817-4 |
| Registry | NCT01992952 |
| Phase | Phase 1, Phase 2 |
| Conditions | Estrogen Receptor Positive Breast Cancer |
| Interventions | AZD5363, Placebo, Fulvestrant |
| Sponsor | Velindre NHS Trust |
| Enrolment | 149 |
| Source licence | Figure published under CC BY 4.0 |
Progression-free survival
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Fulvestrant plus capivasertib 10.3 months; Fulvestrant plus placebo 4.8 months. Survival at 12 months: Fulvestrant plus capivasertib 45%; Fulvestrant plus placebo 20%. Hazard ratio Fulvestrant plus capivasertib vs Fulvestrant plus placebo 0.56 (95% CI 0.38–0.82).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Fulvestrant plus capivasertib | 69 | 49 | 10.3 |
| Fulvestrant plus placebo | 71 | 62 | 4.8 |
- Fulvestrant plus capivasertib vs Fulvestrant plus placebo: reconstructed HR 0.56 (95% CI 0.38–0.82)
Landmark survival (reconstructed)
| Time | Fulvestrant plus capivasertib | Fulvestrant plus placebo |
|---|---|---|
| 6 mo | 62.4% | 43.3% |
| 12 mo | 44.9% | 20.0% |
| 18 mo | 28.7% | 10.9% |
| 24 mo | 17.4% | 1.8% |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.58, reconstructed 0.563 pass
Overall survival
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Fulvestrant plus capivasertib 26.0 months; Fulvestrant plus placebo 20.0 months. Survival at 12 months: Fulvestrant plus capivasertib 80%; Fulvestrant plus placebo 80%. Hazard ratio Fulvestrant plus capivasertib vs Fulvestrant plus placebo 0.55 (95% CI 0.31–0.97).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Fulvestrant plus capivasertib | 69 | 20 | 26.0 |
| Fulvestrant plus placebo | 71 | 32 | 20.0 |
- Fulvestrant plus capivasertib vs Fulvestrant plus placebo: reconstructed HR 0.55 (95% CI 0.31–0.97)
Landmark survival (reconstructed)
| Time | Fulvestrant plus capivasertib | Fulvestrant plus placebo |
|---|---|---|
| 6 mo | 96.6% | 95.1% |
| 12 mo | 80.4% | 80.3% |
| 18 mo | 70.2% | 53.3% |
| 24 mo | 50.9% | 16.5% |
| 36 mo | — | — |
Checks against the published figure
- hazard ratio (direction inferred): printed 0.59, reconstructed 0.55 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/faktion-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/faktion-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Lancet Oncol. 2020 Mar;21(3):345–57. doi: 10.1016/S1470-2045(19)30817-4 doi:10.1016/S1470-2045(19)30817-4. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/faktion
Report a problem with these data
Related trials
- FURVA: Overall survival; Progression-free survival
- Culmerciclib + fulvestrant in HR+/HER2− breast cancer: Overall survival
- NK105 vs paclitaxel in metastatic breast cancer: Overall survival; Progression-free survival
- CirCe01: Overall survival; Progression-free survival
- DATA (10-year update): Adapted breast cancer-free interval (cumulative incidence of breast cancer events); Adapte
- ACE-Breast-02: Overall survival; Progression-free survival assessed by BICR; Progression-free survival as
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials